We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

QUIDEL

Develops, manufactures and markets rapid diagnostic tests at the point-ofcare (POC) that focus on infectious diseases... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Quidel Partners with Global Lyme Alliance, Leads in Lyme Disease Testing

By LabMedica International staff writers
Posted on 14 Jun 2022
Print article
Image: Sofia 2 Lyme FIA is the only FDA-approved rapid POC test on the market (Photo courtesy of Quidel)
Image: Sofia 2 Lyme FIA is the only FDA-approved rapid POC test on the market (Photo courtesy of Quidel)

Lyme disease is a growing epidemic and more than 14% of the world’s population probably has, or has had, the tick-borne disease, as indicated by the presence of antibodies in the blood. Borrelia burgdorferi sensu lato (Bb) infection, more usually known as Lyme disease, is the most common type of tick-borne infection, with ticks second only to mosquitoes in terms of their carriage of harmful microbes. Redness and swelling at the site of the tick bite is typical, but the infecting agent can spread to other tissues and organs, potentially affecting the nervous system, joints, heart and skin. Lyme disease has continued to spread around the world, but there’s no agreement on just how common it is globally, or what the specific risk factors might be.

Now, Quidel Corporation (San Diego, CA, USA) is joining forces with Global Lyme Alliance (Stamford, CT, USA) to heighten public awareness around Lyme disease during Lyme Disease Awareness Month (in May) and beyond. Quidel is the leading developer in the US of the only FDA-approved rapid point of care diagnostic Lyme disease test. As part of its partnership, Quidel serves as GLA’s Official Sponsor during Lyme Awareness Month and will partner on a series of educational PACE accredited webinars. The webinars will provide new information on various Lyme topics in an open discussion format, all designed to bring awareness to Lyme disease, along with rapid ways to diagnose Lyme, leading to prompt treatment.

Leading the way in Lyme disease testing is Quidel’s Sofia 2 Lyme FIA. The only FDA-approved rapid point of care test on the market provides the patient and their physician with indicative results within 15 minutes instead of days, which has historically been the norm. Performed in the privacy of a doctor’s office or local clinic, it is also the only test that can get results from a simple finger prick of blood.

Related Links:
Quidel Corporation 
Global Lyme Alliance 

Flocked Swab
HydraFlock and PurFlock Ultra
Gold Supplier
Procalcitonin Test
LIAISON B•R•A•H•M•S PCT II GEN
New
Cardiac Test
ImmunTech Cardiac Triple Test
New
IFA Automation Solution
dIFine 30 System

Print article

Channels

Clinical Chem.

view channel
Image: Electrochemical cells etched by laser on wooden tongue depressor measure glucose and nitrite in saliva (Photo courtesy of Analytical Chemistry)

Biosensor-Fabricated Wooden Tongue Depressor Measures Glucose and Nitrite in Saliva

Physicians often use tongue depressors to examine a patient's mouth and throat. However, it is hard to imagine that this simple wooden tool could actively assess a patient's health. This idea has led to... Read more

Hematology

view channel
Image: The Atellica HEMA 570 and 580 hematology analyzers remove workflow barriers (Photo courtesy of Siemens)

Next-Gen Hematology Analyzers Eliminate Workflow Roadblocks and Achieve Fast Throughput

Hematology testing is a critical aspect of patient care, utilized to establish a patient's health baseline, track treatment progress, or guide timely modifications to care. However, increasing constraints... Read more

Immunology

view channel
Image: Newly observed anti-FSP antibodies have also been found to predict immune-related adverse events (Photo courtesy of Calviri)

First Blood-Based Biomarkers Test to Predict Treatment Response in Cancer Patients

Every year worldwide, lung cancer afflicts over two million individuals and almost the same number of people succumb to the disease. This malignancy leads the charts in cancer-related mortalities, with... Read more

Microbiology

view channel
Image: The rapid MTB strip test for tuberculosis can identify TB patients within two hours (Photo courtesy of Chulalongkorn University)

Rapid MTB Strip Test Detects Tuberculosis in Less Than an Hour without Special Tools

Tuberculosis (TB), a highly infectious disease, continues to pose significant challenges to public health worldwide. TB is caused by a bacterium known as "Mycobacterium tuberculosis," spreading through... Read more

Pathology

view channel
Image: The UNIQO 160 (CE-IVDR) advances diagnostic analysis for autoimmune diseases (Photo courtesy of EUROIMMUN)

Novel Automated IIFT System Enables Cutting-Edge Diagnostic Analysis

A newly-launched automated indirect immunofluorescence test (IIFT) system for autoimmune disease diagnostics offers an all-in-one solution to enhance the efficiency of the complete IIFT process, comprising... Read more

Technology

view channel
Electronic biosensor uses DNA aptamers for detecting biomarkers in whole blood samples (Photo courtesy of Freepik)

Electronic Biosensor Detects Biomarkers in Whole Blood Samples without Addition of Reagents

The absence of robust, reliable, and user-friendly bioanalytical tools for early and timely diagnosis of cardiovascular diseases, particularly sudden cardiac arrest, leads to preventable deaths and imposes... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.